help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Florio, T.
Right arrow Articles by Schettini, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Florio, T.
Right arrow Articles by Schettini, G.
Molecular Endocrinology 15 (10): 1838-1852
Copyright © 2001 by The Endocrine Society

The Activation of the Phosphotyrosine Phosphatase {eta} (r-PTP{eta}) Is Responsible for the Somatostatin Inhibition of PC Cl3 Thyroid Cell Proliferation

Tullio Florio, Sara Arena, Stefano Thellung, Rodolfo Iuliano, Alessandro Corsaro, Alessandro Massa, Alessandra Pattarozzi, Adriana Bajetto, Francesco Trapasso, Alfredo Fusco and Gennaro Schettini

Pharmacology and Neuroscience (T.F., S.A., S.T., A.C., A.M., A.P., A.B., G.S.), National Institute for Cancer Research (IST) and Advanced Biotechnology Center (CBA) Genova 16132, Italy; Department of Biomedical Sciences (T.F.), Section of Pharmacology, University G. D’Annunzio of Chieti, Chieti 66013, Italy; Department of Oncology Biology and Genetics (S.A., S.T., A.C., A.M., A.P., A.B., G.S.), Section of Pharmacology, University of Genova 16132, Italy; Department of Clinical and Experimental Medicine (R.I., F.T., A.F.) University of Catanzaro, Catanzaro 88100, Italy

Address all correspondence and requests for reprints to: Professor Gennaro Schettini, Neuroscience and Pharmacology, Advanced Biotechnology Center (CBA), Largo R. Benzi, 10, 16132 Genova, Italy. E-mail: schettini{at}cba.unige.it

The aim of this study was the characterization of the intracellular effectors of the antiproliferative activity of somatostatin in PC Cl3 thyroid cells. Somatostatin inhibited PC Cl3 cell proliferation through the activation of a membrane phosphotyrosine phosphatase. Conversely, PC Cl3 cells stably expressing the v-mos oncogene (PC mos) were completely insensitive to the somatostatin antiproliferative effects since somatostatin was unable to stimulate a phosphotyrosine phosphatase activity. In PC mos cells basal phosphotyrosine phosphatase activity was also reduced, suggesting that the expression of a specific phosphotyrosine phosphatase was impaired in these transformed cells. We suggested that this phosphotyrosine phosphatase could be r-PTP{eta} whose expression was abolished in the PC mos cells. To directly prove the involvement of r-PTP{eta} in somatostatin’s effect, we stably transfected this phosphatase in PC mos cells. This new cell line (PC mos/PTP{eta}) recovered somatostatin’s ability to inhibit cell proliferation, showing dose-dependence and time course similar to those observed in PC Cl3 cells. Conversely, the transfection of a catalytically inactive mutant of r-PTP{eta} did not restore the antiproliferative effects of somatostatin. PC mos/PTP{eta} cells showed a high basal phosphotyrosine phosphatase activity which, similarly to PC Cl3 cells, was further increased after somatostatin treatment. The specificity of the role of r-PTP{eta} in somatostatin receptor signal transduction was demonstrated by measuring its specific activity after somatostatin treatment in an immunocomplex assay. Somatostatin highly increased r-PTP{eta} activity in PCCl3 and PC mos/PTP{eta} (+300%, P < 0.01) but not in PCmos cells. Conversely, no differences in somatostatin-stimulated SHP-2 activity, (~ +50%, P < 0.05), were observed among all the cell lines. The activation of r-PTP{eta} by somatostatin caused, acting downstream of MAPK kinase, an inhibition of insulin-induced ERK1/2 activation with the subsequent blockade of the phosphorylation, ubiquitination, and proteasome degradation of the cyclin-dependent kinase inhibitor p27kip1. Ultimately, high levels of p27kip1 lead to cell proliferation arrest. In conclusion, somatostatin inhibition of PC Cl3 cell proliferation requires the activation of r-PTP{eta} which, through the inhibition of MAPK activity, causes the stabilization of the cell cycle inhibitor p27kip1.




This article has been cited by other articles:


Home page
EndocrinologyHome page
F. Barbieri, A. Pattarozzi, M. Gatti, C. Porcile, A. Bajetto, A. Ferrari, M. D. Culler, and T. Florio
Somatostatin Receptors 1, 2, and 5 Cooperate in the Somatostatin Inhibition of C6 Glioma Cell Proliferation in Vitro via a Phosphotyrosine Phosphatase-{eta}-Dependent Inhibition of Extracellularly Regulated Kinase-1/2
Endocrinology, September 1, 2008; 149(9): 4736 - 4746.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
T. Florio, F. Barbieri, R. Spaziante, G. Zona, L. J Hofland, P. M van Koetsveld, R. A Feelders, G. K Stalla, M. Theodoropoulou, M. D Culler, et al.
Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study
Endocr. Relat. Cancer, June 1, 2008; 15(2): 583 - 596.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. Arena, A. Pattarozzi, A. Massa, J.-P. Esteve, R. Iuliano, A. Fusco, C. Susini, and T. Florio
An Intracellular Multi-Effector Complex Mediates Somatostatin Receptor 1 Activation of Phospho-Tyrosine Phosphatase {eta}
Mol. Endocrinol., January 1, 2007; 21(1): 229 - 246.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
S. Romano, A. Muscella, C. Storelli, and S. Marsigliante
Angiotensin II does not stimulate proliferation of rat thyroid PC Cl3 cell line
J. Endocrinol., December 1, 2006; 191(3): 727 - 735.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Massa, F. Barbieri, C. Aiello, S. Arena, A. Pattarozzi, P. Pirani, A. Corsaro, R. Iuliano, A. Fusco, G. Zona, et al.
The Expression of the Phosphotyrosine Phosphatase DEP-1/PTP{eta} Dictates the Responsivity of Glioma Cells to Somatostatin Inhibition of Cell Proliferation
J. Biol. Chem., July 9, 2004; 279(28): 29004 - 29012.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T. Florio, M. Morini, V. Villa, S. Arena, A. Corsaro, S. Thellung, M. D. Culler, U. Pfeffer, D. M. Noonan, G. Schettini, et al.
Somatostatin Inhibits Tumor Angiogenesis and Growth via Somatostatin Receptor-3-Mediated Regulation of Endothelial Nitric Oxide Synthase and Mitogen-Activated Protein Kinase Activities
Endocrinology, April 1, 2003; 144(4): 1574 - 1584.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
B. Banihashemi and P. R. Albert
Dopamine-D2S Receptor Inhibition of Calcium Influx, Adenylyl Cyclase, and Mitogen-Activated Protein Kinase in Pituitary Cells: Distinct G{alpha} and G{beta}{gamma} Requirements
Mol. Endocrinol., October 1, 2002; 16(10): 2393 - 2404.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2001 by The Endocrine Society